It was shown that certain somatic mutations within the kinase domain of EGFR sensitize cancers to treatment with EGFR-specific tyrosine kinase inhibitors (TKIs), such as erlotinib or gefitinib (reviewed in [3]). This evidence concerns the gene EGFR and cancer.